Certain species of wasps and frogs share a pain and inflammation peptide similar to one found in vertebrates to help defend against predators—a discovery that contributes to a shifting view of how ...
Certain species of wasps and frogs share a pain and inflammation peptide similar to one found in vertebrates to help defend ...
Hangzhou Yirui Pharmaceutical Technology Co. Ltd. has described N-tetrazolyl aryl urea derivatives acting as bradykinin B1 receptor antagonists reported to be useful for the treatment of age-related ...
Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...
RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution ...
Pharvaris, a late-stage biopharmaceutical company based in Zug, Switzerland, has announced a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" scheduled for June 4, 2025. This event will ...
Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results